TORNTPHARM vs WANBURY: Stock Comparison
TORRENT PHARMACEUTICALS L is the larger company by market capitalisation. TORRENT PHARMACEUTICALS L shows a higher dividend yield, faster revenue growth and a higher net margin, while WANBURY shows a lower P/E, a higher ROE and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
TORNTPHARM leads 6; WANBURY leads 7 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | TORNTPHARM | WANBURY |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | TORNTPHARM | WANBURY |
|---|---|---|
| Live Price | ₹4,640.1 | ₹186.44 |
| Day Change | 1.31% | 2.48% |
| Volume | 1.57 L | 1.27 L |
| 52-Week High | ₹5,250 | ₹358.85 |
| 52-Week Low | ₹3,532.6 | ₹161.5 |
| Distance from 52W High | -11.62% | -48.05% |
Valuation
| Metric | TORNTPHARM | WANBURY |
|---|---|---|
| Market Cap | ₹1.77 L Cr | ₹632 Cr |
| P/E Ratio | 74.8x | 0x |
| P/B Ratio | 8.41x | 0x |
| EPS | ₹14.04 | ₹4.1 |
| Book Value | ₹462.32 | ₹43.94 |
| Dividend Yield | 0.83% | 0% |
Growth
| Metric | TORNTPHARM | WANBURY |
|---|---|---|
| Revenue Growth (TTM YoY) | 41.8% | -19.2% |
| EPS Growth (TTM YoY) | -21.7% | 0% |
| Qtr Sales Growth | 1.18% | 0% |
| Qtr Profit Growth | -5.65% | 0% |
Profitability & Leverage
| Metric | TORNTPHARM | WANBURY |
|---|---|---|
| ROE | 25.93% | 45.78% |
| ROCE | 10.87% | 25.06% |
| Net Margin | 15.73% | 10.17% |
| Operating Margin | 30.23% | 13.81% |
| Debt to Equity | 1.68x | 1.49x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | TORNTPHARM | WANBURY |
|---|---|---|
| Promoter Holding | 60.78% | 34.33%▼ 0.03 pp |
| FII Holding | 17.22%▼ 0.75 pp | 0.71%▼ 0.18 pp |
| DII Holding | 13.46%▲ 0.59 pp | 0.02%▼ 0.04 pp |
| Public Holding | 8.54%▲ 0.16 pp | 56.28%▲ 0.25 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: TORRENT PHARMACEUTICALS L and WANBURY.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.